<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961257</url>
  </required_header>
  <id_info>
    <org_study_id>CABASTY</org_study_id>
    <nct_id>NCT02961257</nct_id>
  </id_info>
  <brief_title>Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel</brief_title>
  <acronym>CABASTY</acronym>
  <official_title>Randomized Multicenter, Phase III Trial Evaluating the Safety of 2 Schedules of Cabazitaxel (Bi-weekly Versus Tri-weekly) Plus Prednisone in Elderly Men (≥ 65years) With mCRPC Previously Treated With a Docetaxel-containing Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the incidence of grade ≥ 3 neutropenia and/or
      neutropenic complications (febrile neutropenia, neutropenic infection) with two schedules of
      cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men (≥ 65 years) with
      mCRPC previously treated with a docetaxel-containing regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, open-label, phase 3 trial in mCRPC patients aged ≥ 65 years.

      Number of subjects:

      Total:170 (85 per arm)

      Treatment:

        -  Arm A : cabazitaxel 25 mg/m² on Day 1 of a 3-week cycle plus daily prednisone or

        -  Arm B: cabazitaxel 16 mg/m² on Day 1 and Day 15 of a 4-week cycle plus daily prednisone.

        -  Treatment will be continued for a maximum of 10 cycles unless there is documented
           disease progression or unacceptable toxicity.

        -  Standard cabazitaxel premedication will be used

        -  Prophylactic G-CSF (GRANOCYTE) will be injected from Day 3 to Day 7 after every
           administration cycle of cabazitaxel· All new hormonal treatment, including ODM-201,
           prior to study entry is allowed.

        -  Patients who received Radium-223 are eligible for this study

        -  Treatment with LHRH should not be discontinued.

      Exploratory assessments:

      CT-Scan (abdominal/pelvic/chest) or whole body MRI and Bone scan: at screening, every 3
      months and EOT.

      FACT-P questionnaire:at C1D1,each subsequent visit and EOT

      Exploratory substudy Blood samples will be collected in France (4 or 6 sites) and the
      Netherlands (2 sites). Biomarker analysis will be conducted at the Urology and The Tumor
      Immunology Laboratory at Radboud UMC in NL.

      Biomarker schedule Arm A (25mg/m2): Baseline - Week 6 - Week 12 - at progression Arm B
      (16mg/m2): Baseline - Week 6 - Week 12 - at progression Optional sample points are at C1D8.

      Number of subjects: 50

      Statistical analysis:

      A sample size of 77 evaluable patients per arm will achieve 80% power to detect a 20%
      difference in G3 neutropenia incidence between the 2 arms. The incidence in group cabazitaxel
      25 mg/m2 q3w is assumed to be 32% and 12% on bi-weekly cabazitaxel arm. The test used is a
      two-sided Fisher's exact test at 0.05 significance level. Assuming 10% non-evaluable
      patients, 85 patients should be included in each arm for a total of 170. Patients will be
      stratified according to G8 score(&lt; 14 vs. ≥ 14), and age (&lt; 70 vs. ≥ 70) before
      randomization.

      Exploratory sub-study The trial is powered on a clinical endpoint, namely to detect a 20%
      difference in G3 neutropenia incidence between arms (32% in arm A vs 12% arm B; power 80%
      with two-sided alpha of 5%, correcting for 10% non-evaluable patients (=17 patients).

      From the 153 evaluable patients, we have 76 patients in each arm, of which we expect 50-60
      evaluable patients for translational studies (calculations performed on 25 per arm).

      In arm A we expect 8 patients (32% of patients) with G3 neutropenia, and 17 patients that do
      not. In arm B we expect 3 patients (12% of patients) with G3 neutropenia, and 22 patients
      that do not. For the MDSC analyses, we therefore will be comparing 11 patients with G3
      neutropenia to 39 patients.

      For all continuous variables, including all immune subpopulations present in blood, mean (sd)
      will be presented if the distribution seems to be symmetric and in case of a skewed
      distribution the median and IQR. For categorical data, number and percentage will be
      presented. For comparison of continuous data linear regression analyses or correlation
      (Spearman or Pearson) will used. For comparison of continuous data with categorical data
      logistic regression analysis will be used. For comparison of two sets of categorical data the
      chi-square test of Fisher‟s exact test will be utilized. For the radiological PFS analyses
      the estimates of the hazard ratio and corresponding 95% confidence interval will be tested
      using a Cox Proportional hazard model. For the overall survival, a stratified log-rank test
      will be used to compare between groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2017</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of grade ≥ 3 neutropenia and/or neutropenic complications</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>To evaluate the incidence of grade ≥ 3 neutropenia (measured at Day 7 and Day 14) and/or neutropenic complications (febrile neutropenia, neutropenic infection) with two schedules of cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men (≥ 65 years) with mCRPC previously treated with a docetaxel-containing regimen.
with two schedules of -+cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men with mCRPC previously treated with a docetaxel-containing regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose reductions</measure>
    <time_frame>through study completion, an average of 40 weeks</time_frame>
    <description>Up to 11 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological progression-free survival (rPFS)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>CT-Scan (abdominal/pelvic/chest) or whole body MRI and Bone scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Assessed at C1D1, at every each subsequent visit and EOT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first symptomatic Skeletal-Related Event (SRE) and incidence of SREs</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Assessed at C1D1, at every each subsequent visit and EOT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to opioid treatment (if relevant)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific antigen (PSA) response rate</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Assessed at C1D1, at every each subsequent visit and EOT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (FACT-P)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Assessed at C1D1, at every each subsequent visit and EOT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) in measurable lesions (RECIST criteria 1.1 - only on metastasis</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>CT-Scan (abdominal/pelvic/chest) or whole body MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors influencing survival</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Factors influencing survival (duration of response to first ADT, serum testosterone, cumulative dose of cabazitaxel, neutrophils/lymphocytes ratio, Gleason score, G8, grade ≥3 neutropenia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of grade ≥3 neutropenia</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Hematology every week until EOT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade ≥3 neutropenia duration ( from date of onset of grade ≥ 3 until grade ≤ 2)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Hematology every week until EOT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of grade ≥3 neutropenia by cycle</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Analysis of grade ≥3 neutropenia and/or neutropenia by cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose delay</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of patients achieving a best objective response of SD, PR or CR according to RECIST 1.1 specifically comparing those achieving &gt;30% and &gt;50% decrease in MDSC post-induction compared to those who did not achieve this reduction.</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Biomarker analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients achieving a &gt;50% PSA response at 12 weeks and at any time specifically comparing those achieving &gt;30% and &gt;50% decrease in MDSC post-induction compared to those who did not achieve this reduction.</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Exploratory sub-study: biomarker analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Radiological progression-free survival (rPFS) according to PCWG2 criteria for all patients, in relation to percentage MDSC change (% maximum change and those achieving &gt;30% and &gt;50% decrease)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Exploratory sub-study: biomarker analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlations between extent of MDSC (continuous) and NLR decline (continuous)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Exploratory sub-study: biomarker analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Differences in peripheral blood immune populations (MDSCs, regulatory T-cells, T-effector and natural killer [NK] cells) with cabazitaxel responsiveness for Q2W and Q3W dosing schedule at week 6 and week 12</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>biomarkers analysis
collection of blood (EDTA tube) at Baseline, C1D8,week 6, week 12 and EOT Collection of blood (RNA Paxgene): baseline
platelet poor plasma isolation, PBMC isolation, PMN isolation and
Flow cytometry assessments and FACS sorting Next-generation targeted sequencing of cfDNA RNA sequencing of baseline PaxGene</description>
  </other_outcome>
  <other_outcome>
    <measure>correlation between MDSC decline (&gt;30% or &gt;50%) with neutropenia (presence or absence)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Hematology every week until EOT
collection of blood (EDTA tube) at Baseline, C1D8,week 6, week 12 and EOT Collection of blood (RNA Paxgene): baseline
platelet poor plasma isolation, PBMC isolation, PMN isolation and
Flow cytometry assessments and FACS sorting Next-generation targeted sequencing of cfDNA RNA sequencing of baseline PaxGene</description>
  </other_outcome>
  <other_outcome>
    <measure>Associations between cabazitaxel dose, presence of neutropenia (C1D8), NLR conversion (wk6 and wk12) and MDSC decline (wk6 and wk12)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>biomarkers analysis
collection of blood (EDTA tube) at Baseline, C1D8,week 6, week 12 and EOT Collection of blood (RNA Paxgene): baseline
platelet poor plasma isolation, PBMC isolation, PMN isolation and
Flow cytometry assessments and FACS sorting Next-generation targeted sequencing of cfDNA RNA sequencing of baseline PaxGene</description>
  </other_outcome>
  <other_outcome>
    <measure>To evaluate changes in peripheral blood immune populations at failure on cabazitaxel, with particular focus on CD38-positive MDSC subsets</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>biomarkers analysis
collection of blood (EDTA tube) at Baseline, C1D8,week 6, week 12 and EOT Collection of blood (RNA Paxgene): baseline
platelet poor plasma isolation, PBMC isolation, PMN isolation and
Flow cytometry assessments and FACS sorting Next-generation targeted sequencing of cfDNA RNA sequencing of baseline PaxGene</description>
  </other_outcome>
  <other_outcome>
    <measure>Associations between baseline MDSC and molecular underpinning (from cfDNA, specifically studying MYCN amplification and PTEN / TP53 aberration)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>biomarkers analysis
collection of blood (EDTA tube) at Baseline, C1D8,week 6, week 12 and EOT Collection of blood (RNA Paxgene): baseline
platelet poor plasma isolation, PBMC isolation, PMN isolation and
Flow cytometry assessments and FACS sorting Next-generation targeted sequencing of cfDNA RNA sequencing of baseline PaxGene</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Prostate Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabazitaxel 25 mg/m² intravenously over 1 hour on Day 1of a 3-week cycle, plus prednisone (or prednisolone) 10 mg orally given daily for a maximum of 10 cycles (ie 30 weeks of treatment).
Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabazitaxel 16 mg/m2 on Day 1 and Day 15 of a 4-week cycle plus prednisone (or prednisolone) 10 mg per day up to 10 cycles (ie 40 weeks of treatment). Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cabazitaxel</intervention_name>
    <description>Arm A : cabazitaxel 25 mg/m² on Day 1 of a 3-week cycle plus daily prednisone or
Arm B: cabazitaxel 16 mg/m² on Day 1 and Day 15 of a 4-week cycle plus daily prednisone.
Treatment will be continued for a maximum of 10 cycles unless there is documented disease progression or unacceptable toxicity.
Standard cabazitaxel premedication will be used</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Jevtana</other_name>
    <other_name>XRP6258</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Arm A:plus prednisone 10 mg orally given daily for a maximum of 10 cycles Arm B: plus prednisone 10 mg orally given per day up to 10 cycles</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte colony-stimulating factor (G-CSF)</intervention_name>
    <description>Primary prophylaxis with Granulocyte Colony-Stimulating Factor (G-CSF) will be injected from Day 3 to Day 7 after every administration of cabazitaxel</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Granocyte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient aged ≥ 65 years with mCRPC previously treated with docetaxel

          2. Medical or surgical castration with castrate level of testosterone (&lt; 50 ng/dl) based
             on the EAU definition of castrate level of testosterone

          3. Progressive disease according to PCWG2

          4. Histologically proven prostate carcinoma

          5. Health status allowing use of chemotherapy: G8 &gt; 14; or G8 score ≤ 14 with geriatric
             assessment concluding to reversible impairment allowing use of chemotherapy

          6. ECOG-PS 0, 1 or 2(ECOG-PS 2 should be related to prostate cancer)

          7. Adequate hematologic, liver and renal functions:

               1. Neutrophil count ≥1.5 109/L

               2. Haemoglobin ≥10 g/ dL

               3. Platelet count ≥100.109/L

               4. Total bilirubin ≤ 1 the upper limit of normal (ULN)

               5. Transaminases ≤ 1.5 ULN

               6. Serum creatinine ≤ 2.0 ULN

          8. Ongoing LHRH therapy at study entry

          9. Signed informed consent

        Exclusion Criteria:

          1. History of severe hypersensitivity reaction (≥grade 3) to docetaxel

          2. History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing
             drugs

          3. Uncontrolled severe illness or medical condition (including uncontrolled diabetes
             mellitus)

          4. Concurrent or planned treatment with strong inhibitors or strong inducers of
             cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are
             already on these treatments) (see Appendix E)

          5. PS &gt;2 not related to prostate cancer disease

          6. G8 ≤ 14 with geriatric assessment contra-indicating standard cabazitaxel regimen

          7. Concomitant vaccination with yellow fever vaccine

          8. Patient who cannot be regularly followed or cannot answer to quality of life
             questionnaires because of psychological, social, familial or geographic reasons

          9. Participation in another clinical trial with any investigational drug within 30 days
             prior to study enrolment.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephane OUDARD, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen Georges Pompidou, Oncology Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Réza ELAIDI, PhD</last_name>
    <phone>00 33 (1)56 09 23 40</phone>
    <email>reza-thierry.elaidi-ext@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Houda BELHOUARI, MD</last_name>
    <email>houda.belhouari-ext@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine THIERY-VUILLEMIN, MD</last_name>
      <email>a.thieryvuillemin@mac.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint André, CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amandine QUIVY, MD</last_name>
      <email>amandine.quivy@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur-CFRO</name>
      <address>
        <city>Brest</city>
        <zip>29229</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali HASBINI</last_name>
    </contact>
    <contact_backup>
      <email>alihasbini@oncologie-brest.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Ali HASBINI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Maurice Tubiana</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>e.sevin@i-l-c.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel SEVIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique Saint-Côme</name>
      <address>
        <city>Compiègne</city>
        <zip>60204</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kais ALDABBAGH, MD</last_name>
      <email>Kais.aldabbagh@stcome.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Henri-Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>carolina.saldana@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Carolina SALDANA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric VOOG</last_name>
    </contact>
    <contact_backup>
      <email>e.voog@cjb72.org</email>
    </contact_backup>
    <investigator>
      <last_name>Eric VOOG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>T-Ryckewaert@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas RYCKEWAERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Belle-Isle</name>
      <address>
        <city>Metz</city>
        <zip>57045</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérôme PLAZA, MD</last_name>
      <email>jerome.plaza@hp-metz.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GHIRM</name>
      <address>
        <city>Montfermeil</city>
        <zip>93370</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ida PAVESE</last_name>
    </contact>
    <contact_backup>
      <email>ipavese@ch-montfermeil.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Ida PAVESE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie du Gard - CHU</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>nadine.HOUEDE@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Nadine HOUEDE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mostefa BENNAMOUN, MD</last_name>
      <email>Mostefa.Bennamoun@imm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane OUDARD, MD</last_name>
      <phone>00 33 (1) 56 09 34 76</phone>
      <email>stephane.oudard@egp.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmed KHALIL, MD</last_name>
      <email>ahmed.khalil@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme ALEXANDRE, MD</last_name>
      <email>jerome.alexandre@cch.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marc TOURANI, MD</last_name>
      <email>Jean-Marc.TOURANI@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric DI FIORE, MD</last_name>
      <email>Frederic.DiFiore@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine de Radiologie</name>
      <address>
        <city>Saint-brieuc</city>
        <zip>22015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Claire HARDY-BESSARD, MD</last_name>
      <email>ac.hardy@cario-sante.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIA Bégin 69 avenue de Paris</name>
      <address>
        <city>Saint-Mandé</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole HELISSEY, MD</last_name>
      <email>carole.helissey@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Sens</name>
      <address>
        <city>Sens</city>
        <zip>89100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laure CHAUVENET, MD</last_name>
      <email>LCHAUVENET@ch-sens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>philippe.barthelemy@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe BARTHELEMY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital FOCH</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>p.beuzeboc@hopital-foch.com</email>
    </contact>
    <investigator>
      <last_name>Philippe BEUZEBOC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de cancérologie Les Dentellières</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaovi Éric AMELA</last_name>
    </contact>
    <contact_backup>
      <email>amela@lesdentellieres.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yaovi Éric AMELA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologisch-onkologische Schwerpunktpraxis</name>
      <address>
        <city>Bernburg</city>
        <zip>06406</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urologie und Kinderurologie Marienkrankenhaus Bergisch</name>
      <address>
        <city>Gladbach</city>
        <zip>51465</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Machtens, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunhild von Amsberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-klinik für Urologie und Kinderurologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Schostak, MD</last_name>
      <email>martin.schostak@med.ovgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis am Hasselbachplatz</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik für Urologie und Kinderurologie,</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Bögemann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Studienpraxis Urologie</name>
      <address>
        <city>Nürtingen</city>
        <zip>72622</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Feyerabend, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboudumc Medische Oncologie</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CWZ Department of Oncology</name>
      <address>
        <city>Nijmegen</city>
        <zip>6532</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 22, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2016</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

